Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$42.5B |
| 2 |
NVIDIA
NVDA
|
+$2.39B |
| 3 |
Walmart Inc
WMT
|
+$1.17B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.08B |
| 5 |
JPMorgan Chase
JPM
|
+$808M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.26B |
| 2 |
Amazon
AMZN
|
+$843M |
| 3 |
Xcel Energy
XEL
|
+$674M |
| 4 |
Global Payments
GPN
|
+$623M |
| 5 |
Palantir
PLTR
|
+$577M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 46.22% |
| 2 | Technology | 18.11% |
| 3 | Financials | 7.1% |
| 4 | Communication Services | 5.53% |
| 5 | Consumer Discretionary | 5.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3026
Lineage Cell Therapeutics
LCTX
$235M
| $621K | ﹤0.01% |
393,309
+44,799
| +13% | +$75.5K |
2022 Q3
14 quarters
|
|
3027
Stoneridge
SRI
$192M
| $620K | ﹤0.01% |
128,295
+37,088
| +41% | +$254K |
2013 Q2
51 quarters
|
|
3028
Relmada Therapeutics
RLMD
$384M
| $619K | ﹤0.01% |
88,953
+28,953
| +48% | +$137K |
2025 Q2
3 quarters
|
|
3029
Acadia Pharmaceuticals
ACAD
$3.44B
| $619K | ﹤0.01% |
27,803
-340,501
| -92% | -$8.14M |
2013 Q2
51 quarters
|
|
|
UBFO
3030
DELISTED
United Security Bancshares
UBFO
| $618K | ﹤0.01% |
58,822
-8,433
| -13% | -$88.6K |
2017 Q2
35 quarters
|
|
3031
10x Genomics
TXG
$12.2B
| $618K | ﹤0.01% |
29,098
-288,884
| -91% | -$5.78M |
2022 Q1
16 quarters
|
|
3032
American Public Education
APEI
$800M
| $616K | ﹤0.01% |
10,833
-23,515
| -68% | -$1.08M |
2013 Q2
51 quarters
|
|
3033
Usana Health Sciences
USNA
$274M
| $616K | ﹤0.01% |
35,241
-14,030
| -28% | -$278K |
2013 Q2
51 quarters
|
|
3034
ArcBest
ARCB
$2.96B
| $613K | ﹤0.01% |
6,232
-32,855
| -84% | -$3.11M |
2016 Q2
39 quarters
|
|
3035
BrightView Holdings
BV
$952M
| $612K | ﹤0.01% |
51,875
-103,871
| -67% | -$1.34M |
2018 Q2
31 quarters
|
|
|
AEXA
3036
American Exceptionalism Acquisition Corp
AEXA
$550M
| $611K | ﹤0.01% |
+56,460
| New | +$639K |
2026 Q1
0 quarters
|
|
3037
Veritone
VERI
$76.1M
| $611K | ﹤0.01% |
309,977
+43,935
| +17% | +$149K |
2021 Q2
19 quarters
|
|
|
AVR
3038
Anteris Technologies
AVR
$751M
| $610K | ﹤0.01% |
109,922
-38,206
| -26% | -$219K |
2025 Q1
4 quarters
|
|
3039
Arbor Realty Trust
ABR
$664M
| $610K | ﹤0.01% |
79,110
-379,325
| -83% | -$2.96M |
2018 Q2
31 quarters
|
|
3040
Transcat
TRNS
$846M
| $610K | ﹤0.01% |
8,299
-13,625
| -62% | -$959K |
2019 Q1
28 quarters
|
|
3041
O-I Glass
OI
$860M
| $607K | ﹤0.01% |
57,774
-188,992
| -77% | -$2.6M |
2022 Q1
16 quarters
|
|
3042
SiriusPoint
SPNT
$2.84B
| $607K | ﹤0.01% |
28,178
-133,475
| -83% | -$2.75M |
2022 Q1
16 quarters
|
|
3043
HCI Group
HCI
$2.29B
| $607K | ﹤0.01% |
3,923
-13,312
| -77% | -$2.18M |
2016 Q3
38 quarters
|
|
3044
The RMR Group
RMR
$303M
| $606K | ﹤0.01% |
39,143
-20,846
| -35% | -$338K |
2019 Q1
28 quarters
|
|
3045
Suzano
SUZ
$10.5B
| $602K | ﹤0.01% |
60,150
+49,500
| +465% | +$500K |
2024 Q2
7 quarters
|
|
3046
iShares Russell 2000 Growth ETF
IWO
$14.1B
| $600K | ﹤0.01% |
1,913
-74,624
| -98% | -$24.8M |
2023 Q1
12 quarters
|
|
3047
Galicia Financial Group
GGAL
$5.76B
| $600K | ﹤0.01% |
12,846
-23,532
| -65% | -$1.14M |
2024 Q2
7 quarters
|
|
3048
ICU Medical
ICUI
$3.99B
| $599K | ﹤0.01% |
4,636
-33,069
| -88% | -$4.75M |
2016 Q3
38 quarters
|
|
3049
Arvinas
ARVN
$485M
| $597K | ﹤0.01% |
56,357
-112,050
| -67% | -$1.39M |
2019 Q1
28 quarters
|
|
3050
Eagle Bancorp
EGBN
$865M
| $595K | ﹤0.01% |
23,914
-41,544
| -63% | -$1.04M |
2013 Q2
51 quarters
|
|
Similar funds
Barclays's Q1 2026 Portfolio in Review
As of Q1 2026, Barclays held 5,572 positions worth $416B, down 0.11% from $417B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Barclays deployed $42.4B of net new capital in Q1 2026, opening 397 new positions and adding to 1,219 existing holdings. Its largest new stake was Sunbelt Rentals Holdings: 1,528,635 shares worth $99.5M.
By sector, the portfolio is most concentrated in Miscellaneous at 46% of assets, up from 44% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Tesla, an estimated $1.26B trimmed.
- Barclays's largest Q1 2026 buy was Sunbelt Rentals Holdings: 1,528,635 shares worth $99.5M.
- Barclays added most to iShares MSCI Emerging Markets ETF in Q1 2026, an estimated $42.5B increase.
- Barclays's biggest Q1 2026 reduction was Tesla, cutting an estimated $1.26B.
- Barclays fully exited CyberArk in Q1 2026, selling an estimated $232M.
- Barclays's ten largest holdings make up 37% of its $416B portfolio in Q1 2026.
- Barclays opened 397 new positions and closed 563 in Q1 2026.
- Barclays's portfolio value fell 0.11% quarter-over-quarter to $416B.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.